In a report released today, Evan Seigerman from BMO Capital reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report), with a price target of $100.00.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight the potential of Structure Therapeutics, Inc. Sponsored ADR. The company’s lead compound, aleniglipron, is positioned as a promising competitor in the obesity treatment market, leveraging its ‘glipron backbone’ which has shown variability in efficacy and tolerability among similar compounds. Despite recent pressures on GPCR shares, Seigerman believes the current market capitalization of $1.1 billion undervalues the opportunities presented by aleniglipron and the company’s advancements in amylin.
Seigerman’s optimism is further supported by the upcoming Phase 2 trials, ACCESS I and II, which are expected to provide significant insights into aleniglipron’s efficacy and tolerability. Additionally, the company’s focus on developing oral GLP-1 products, which offer a more convenient and potentially cost-effective alternative to peptide-based treatments, positions Structure Therapeutics favorably in a market with high unmet needs. Overall, Seigerman’s analysis suggests that the company’s strategic positioning and innovative product pipeline justify a Buy rating.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $87.00 price target.